Theravance Biopharma (TBPH) Cash & Current Investments (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Cash & Current Investments data on file, last reported at $394.7 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 201.61% year-over-year to $394.7 million in Q1 2026; TTM through Mar 2026 was $394.7 million, a 201.61% increase from a year earlier, with the FY2025 full-year figure at $315.4 million, up 256.94% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $394.7 million, up from $315.4 million in the prior quarter.
• Over the last five years, Cash & Current Investments for TBPH reached as high as $486.8 million in Q3 2022 and fell as low as $88.4 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $213.2 million across 5 years, with a median of $147.5 million in 2022.
• Across the five-year window, Cash & Current Investments plunged 72.47% in 2023 and surged 260.85% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $327.5 million in 2022, then slumped by 68.72% to $102.4 million in 2023, then decreased by 13.74% to $88.4 million in 2024, then surged by 256.94% to $315.4 million in 2025, then increased by 25.15% to $394.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $394.7 million in Q1 2026, $315.4 million in Q4 2025, and $329.7 million in Q3 2025.